Medical/Dental Professionals

Research and Clinical Trials

New PDD/LBD Treatment Tested in Clinical Trial

UB's Jacobs School of Medicine and Biomedical Sciences is among 72 sites nationwide that are recruiting patients for a 12-week, randomized, placebo-controlled drug trial for the first treatment designed to benefit patients with mild-to-moderate Lewy body dementia (LBD).

After Alzheimer’s disease, LBD and related Parkinson’s disease dementia (PDD) are some of the most common types of dementia affecting older adults; but they are severely understudied.

While LBD patients are often prescribed medications that treat psychosis and Alzheimer’s disease, there are no medications designed specifically to treat LBD. Eli Lilly and Company has launched a clinical trial in hopes of changing that.

“Participating in this trial could help push this drug more quickly through the pipeline,” says Kinga Szigeti, MD, PhD, associate professor of neurology, who is principal investigator at UB.

Researchers Aim to Advance Surgery With 3D Printing

Researchers have developed a way to generate 3D prints of the human vascular system, giving surgeons pre-surgical, hands-on access to individual patients’ life-threatening vascular diseases in the heart and brain.

The 3D printing method — initiated by Ciprian N. Ionita, PhD, assistant professor of biomedical engineering, and Adnan Siddiqui, MD, PhD, professor of neurosurgery — is already being used to better prepare doctors performing delicate surgeries to treat conditions such as stroke, aneurysms, cardiac arrest and congestive heart failure.

Ionita and Siddiqui began their 3D-printing research when the Clinical and Translational Research Center, Gates Vascular Institute and Jacobs Institute were created to place engineers, physicists and vascular surgeons all under one roof.

Dandona Research Influences European OK of Diabetes Drug

Pioneering research conducted and advanced by Paresh Dandona, MD, PhD, an endocrinologist with UBMD Internal Medicine and SUNY Distinguished Professor of medicine and chief of endocrinology, diabetes and metabolism, played a key role in the European Commission’s decision to approve dapagliflozin for patients with Type 1 diabetes.

Dandona led DEPICT-1 and was the study’s principal investigator and lead author on the paper reporting the trial’s results in The Lancet Diabetes & Endocrinology in September 2017.

“This is a novel oral treatment for Type 1 diabetes, which, when used as an adjunct to insulin, improves the predictability of blood sugar control and provides a real quality of life benefit for patients with the disease," said Dandona.